Q-omics provides the consensus-scored RPL19P20 profile across patient tissues and cancer cell-line models. RPL19P20 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL19P20 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPL19P20 RNA expression shows 7,269 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, COAD, and TGCT as cancer lineages where RPL19P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL19P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL19P20 survival associations across molecular data types. RPL19P20 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL19P20 RNA expression–survival associations across cancer types. High RPL19P20 expression shows unfavorable associations in STAD, LIHC and LUAD, but favorable associations in LGG, THCA and LUSC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for RPL19P20 RNA expression.
This table summarizes RPL19P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL19P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL19P20 shows higher tumor expression in COAD, KIRC, LIHC, READ, UCEC and LUAD. The COAD box plot shows higher RPL19P20 RNA expression in tumor versus normal tissue (log2 FC = +0.294, t-test p < 0.001).
This table shows molecular features associated with RPL19P20 in patient tissues and cancer cell lines. In patient samples, RPL19P20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
